ApoVax, Inc. is a biotechnology company developing novel immunotherapies, which are treatments based on the concept of regulating the immune system to fight disease. For example, the immune system can be activated to fight disease in cases such as cancer and infectious disease (Tuberculosis, Flu), or suppressed in instances of autoimmune disease and organ or tissue transplantation.
The Company's lead immunotherapy is ApoVax104, a novel, flexible, vaccine platform technology being applied to cancer and infectious diseases. In preclinical studies, the vaccine has proven to be much more effective and less toxic than other vaccine components currently being tested in late stage clinical trials by large pharmaceutical companies.
ApoVax104 is a recombinant protein vaccine that can be combined with any antigen to create disease-specific vaccines that have clinical value in a multitude of diseases. The first clinical application for the ApoVax104 platform is ApoVax104-HPV, a novel therapeutic vaccine for cervical cancer which will enter a Phase I clinical trial in Q3 2012.
ApoVax's second platform technology, ProtEx, is a technology that enables recombinant immunoregulatory proteins to be placed on the surface of cells, tissues, organs, and synthetic surfaces in order to modulate the immune system. The lead product for the ProtEx technology is ApoFasL which improves current organ and tissue transplant therapies by protecting the transplant from being attacked by the recipient's immune system when transplanted into the body. An added benefit of the technology is that it also reduces the need for powerful immunosuppressive drugs with highly toxic effects that are required after transplantation. The first clinical application for ApoFasL will be as an insulin replacement therapy for the treatment of Type I Diabetes.
ApoVax, Inc. Awarded Crowe Horwath Innovation Award
ApoVax, Inc. is pleased to announce that is has been selected as winner of the Crowe Horwatch Innovation Award. This award is presented to an individual or organization that has positively impacted healthcare delivery costs through the development, design or implementation of new technology.
ApoVax Named a Top Innovator Winner
ApoVax, Inc. is pleased to announce that it has been
selected as a winner of the annual New England Venture Summit Top Innovator award by
youngStartup Ventures. The list of privately held companies recognizes those that play a
leading role in innovation for the Technology, Life Sciences and Clean-tech sectors.
ApoVax Finalist for "Best Early-Stage Vaccine Biotech" at World Vaccine Congress ViE Awards
ApoVax, Inc., a Louisville-based biotechnology company developing vaccines and immunotherapies was selected as a finalist for "Best Early-Stage Vaccine Biotechnology Company" at the recently held World Vaccine Congress in Washington, DC. The Vaccine Industry Excellence (ViE) Awards are an integral part of the annual World Vaccine Congress and recognize the outstanding achievements of vaccine practitioners and stakeholders across the global industry. These awards have been created to honor and generate recognition of the efforts, accomplishments, and positive contributions of companies and individuals in the vaccine industry.
ApoVax Named 2008 Hot Dozen Company
ApoVax, Inc., a biotechnology company developing immunotherapies, has been named a 2008 Hot Dozen company by Greater Louisville Inc.'s (GLI) ENTERPRISECORP. The Hot Dozen is an annual celebration of 12 locally-owned companies who have benefited from Louisville's entrepreneurial atmosphere and continue to thrive in our region. The companies represent innovation and entrepreneurship in Louisville's business community.